PCPS is a viable lifesaving bridge therapy for acute fulminant myocarditis, requiring careful management of flow support to prevent complications like leg ischemia and multiple organ failure.
Provides benchmark survival data for fulminant myocarditis on percutaneous support; leaves open efficacy without controlled trials.
急性心筋炎は,感冒様症状と心電図異常にとどまる軽症のものから,致死的な不整脈や心不全を生じて急速な経過で心原性ショックに陥り死亡するものまで多彩である。特に急激に発症し,ポンプ失調や重篤な不整脈を併発して急速な経過で心肺危機に陥り,時に死亡するものを劇症型心筋炎という。近年,従来では救命しえなかった劇症型心筋炎症例が,大動脈内バルーンパンピング(intraaortic balloon pumping, IABP),経皮的心肺補助(percutaneous cardiopulmonary support, PCPS)や補助人工心臓(ventricular assistant device, VAS)
No takes yet. Share an insight, caveat, or question.
Naoyoshi Aoyama (2001) conducted a review in Acute fulminant myocarditis (n=52). Percutaneous cardiopulmonary support (PCPS) was evaluated on Survival rate. In a nationwide survey of 52 patients with acute fulminant myocarditis treated with percutaneous cardiopulmonary support, the survival rate was 57.7%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: